Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Current Leases (2019 - 2025)

Historic Current Leases for Perspective Therapeutics (CATX) over the last 7 years, with Q3 2025 value amounting to $704000.0.

  • Perspective Therapeutics' Current Leases fell 2203.77% to $704000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $704000.0, marking a year-over-year decrease of 2203.77%. This contributed to the annual value of $957000.0 for FY2024, which is 198043.48% up from last year.
  • Perspective Therapeutics' Current Leases amounted to $704000.0 in Q3 2025, which was down 2203.77% from $847000.0 recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Current Leases high stood at $980000.0 for Q1 2025, and its period low was $46000.0 during Q4 2023.
  • Moreover, its 5-year median value for Current Leases was $270000.0 (2022), whereas its average is $441166.7.
  • The largest annual percentage gain for Perspective Therapeutics' Current Leases in the last 5 years was 198043.48% (2024), contrasted with its biggest fall of 5428.57% (2024).
  • Perspective Therapeutics' Current Leases (Quarter) stood at $260000.0 in 2021, then rose by 4.62% to $272000.0 in 2022, then plummeted by 83.09% to $46000.0 in 2023, then soared by 1980.43% to $957000.0 in 2024, then decreased by 26.44% to $704000.0 in 2025.
  • Its Current Leases stands at $704000.0 for Q3 2025, versus $847000.0 for Q2 2025 and $980000.0 for Q1 2025.